NCT01492985View on ClinicalTrials.gov

Lipopeptide Immunisation With GTU-multiHIV Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

April 8, 2017

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

Placebos of GTU-multiHIV B and LIPO-5 vaccines

Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%

BIOLOGICAL

GTU-multHIV B vaccine and LIPO-5 vaccine

Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.

Trial Locations (1)

94010

Service d'Immunologie clinique, Centre de vaccination anti-VIH ANRS Mondor Ile-de-France, Hôpital Henri Mondor, Créteil

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT01492985 - Lipopeptide Immunisation With GTU-multiHIV Trial | Biotech Hunter | Biotech Hunter